Supplier Quality Working Group

The Supplier Quality Working Group is made up of Rx-360 consortium member delegates from both pharmaceutical manufacturers and suppliers. In this group, pharmaceutical and supplier members meet virtually to share perspectives and collaborate to develop publications and tools that improve the supply chain to protect patient safety.

Complete the form to request more information and join.

Inquire About the Supplier Qualiy Working Group

Name(Required)
Email(Required)
Please invite me to the next Supplier Quality Working Group virtual meeting.
Please let us know what's on your mind. Have a question for us? Ask away.

 

 
 
 
 
 

Watch thESE Brief Member TestimonialS

“I’m a very active member in the supplier quality working group. It’s benefited me by being able to be part of the solution by helping to shape the quality and regulatory compliance landscape that we all have to work within.”

Jennifer Goodman, Senior Director of Quality at Avantor

 

 

 

 

“Being a part of the Supplier Quality Working group is amazing, number one for networking and meeting new people. And the second is having a chance to collaborate with our industries because in the end, it’s impact to the patients, right? So, we want to make sure we have information available and everybody can use the resources we make sure are possible and available for everybody.”

Karla Longo Gouveia, Supplier Quality Management at Merck

What the 2026 EU GMP Annex 1 Update Means for Veterinary Product Supplier Qualification

 

The 2026 EU GMP Annex 1 changes mark a major regulatory shift, introducing a full separation between human and veterinary manufacturing requirements. As veterinary products move to their own dedicated GMP framework, supplier qualification processes must adapt to a dual‑system reality that increases oversight, complexity, and compliance risk. 

Refer to the following analysis to learn more about the changes and how they impact the pharmaceutical industry. 

Regulatory Split Between Human and Veterinary GMP (effective July 16, 2026) 

Veterinary medicinal products will transition to new GMP regulations, specifically: 

Impact on the Pharmaceutical Industry 

  • Dual Compliance Frameworks: Any company manufacturing both human and veterinary medicinal products must now comply with two different GMP systems instead of one unified Annex 1–based framework.  
  • Quality System Adjustments: Organizations will need to separate documentation, training, procedures, and qualification systems for human vs. veterinary production.  
  • Inspection & Audit Changes: Regulatory inspections for veterinary products will now follow the new implementing regulations rather than the human‑focused Annex 1 guidance, requiring updated readiness plans. 

____________________

END OF ANNEX 1 APPLICABILITY FOR VETERINARY MEDICINAL PRODUCTS

Annex 1 (sterile manufacturing guidance) no longer applies to veterinary products after that date

IMPACT ON THE PHARMACEUTICAL INDUSTRY 

Different Sterile Manufacturing Expectations: Veterinary sterile manufacturing will be governed by new rules, meaning companies may need to revalidate cleanrooms, sterilization processes, and aseptic operations under the new veterinary framework if they produce vet sterile products.

Operational Complexity: Facilities producing both human and vet sterile medicines must maintain two parallel sterility assurance approaches.

Increased Strategic and Operational Burden on Mixed‑Portfolio Manufacturers  

The 2026 regulatory change requires organizations operating in both sectors to: 

  • Reassess facility layouts, quality systems, documentation controls, and product life‑cycle practices to align with the split regulatory routes.  
  • Manage the administrative and cost burden of maintaining compliance with two diverging sets of GMP expectations. 

Impact on the pharmaceutical industry 

  • Higher Costs & Resource Needs: New training, documentation structures, and possibly facility segmentation.  
  • Risk of Non‑Compliance: Companies unprepared for the regulatory separation risk inconsistent compliance across product categories. 

____________________

The core impact of the 2026 updates to EudraLex Volume 4 – Annex 1 is the regulatory separation of human and veterinary GMP requirements. 

Annex 1 continues to apply to human medicinal products. Beginning July 16, 2026, veterinary medicinal products must comply with newly established dedicated veterinary GMP regulations—not Annex 1. 

This regulatory divergence directly affects manufacturing operations, compliance systems, audits, and quality management across the pharmaceutical industry. 

____________________

Refer to the Current EU Annex 1

Get support from Rx-360’s Joint audit Program

____________________

Coming Soon: “How to Prepare for the EU’s New Approach to Regulated Veterinary Products”